Leerink Partners Believes Amicus (FOLD) Still Has Room to Grow
In a report released today, Joseph Schwartz from Leerink Partners maintained a Buy rating on Amicus (FOLD), with a price target of $24.00. The company’s shares closed last Thursday at $21.34, close to its 52-week high of $21.73.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 20.1% and a 52.8% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Chinook Therapeutics.
Currently, the analyst consensus on Amicus is a Strong Buy with an average price target of $23.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.73 and a one-year low of $6.25. Currently, Amicus has an average volume of 1.88M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.